Effect of Food on Abiraterone Pharmacokinetics: A Review

References

• Auchus RJ , YuMK , NguyenS , MundleSD . Use of prednisone with abiraterone acetate in metastatic castration-resistant prostate cancer . Oncologist19 ( 12 ), 1231 – 1240 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Massard C , FizaziK . Targeting continued androgen receptor signaling in prostate cancer . Clin. Cancer Res.17 ( 12 ), 3876 – 3883 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Fizazi K , ScherHI , MolinaAet al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase III study . Lancet Oncol.13 ( 10 ), 983 – 992 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR , FizaziKet al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled Phase III study . Lancet Oncol.16 ( 2 ), 152 – 160 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ratain MJ . Importance of food effects for oral oncology drugs . Clin Adv. Hematol. Oncol.10 ( 6 ), 397 – 398 ( 2012 ).
   PubMedGoogle Scholar
• ZYTIGA® (abiraterone acetate) [US prescribing information] . Horsham, PA : Janssen Biotech Inc. ( 2017 ).
   Google Scholar
• ZYTIGA® (abiraterone acetate) [Europe product information] . European Medicines Agency ( 2016 ).
   Google Scholar
• Acharya M , GonzalezM , MannensGet al. A Phase I, open-label, single-dose, mass balance study of 14C-labeled abiraterone acetate in healthy male subjects . Xenobiotica43 ( 4 ), 379 – 389 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Bernard A , VaccaroN , AcharyaMet al. Impact on abiraterone pharmacokinetics and safety: open-label drug-drug interaction studies with ketoconazole and rifampicin . Clin. Pharmacol. Drug Dev.4 ( 1 ), 63 – 73 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR , FongLet al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy . J. Clin. Oncol.28 ( 9 ), 1481 – 1488 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Attard G , ReidAH , YapTAet al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven . J. Clin. Oncol.26 ( 28 ), 4563 – 4571 ( 2008 ).
   PubMed Web of Science ®Google Scholar
• de Bono JS , LogothetisCJ , MolinaAet al. Abiraterone and increased survival in metastatic prostate cancer . N. Engl. J Med.364 ( 21 ), 1995 – 2005 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Ryan CJ , SmithMR , de BonoJSet al. Abiraterone in metastatic prostate cancer without previous chemotherapy . N. Engl. J Med.368 ( 2 ), 138 – 148 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Gambertoglio JG , AmendWJJr , BenetLZ . Pharmacokinetics and bioavailability of prednisone and prednisolone in healthy volunteers and patients: a review . J Pharmacokinet. Biopharm.8 ( 1 ), 1 – 52 ( 1980 ).
   PubMedGoogle Scholar
• Singh BN , MalhotraBK . Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy . Clin. Pharmacokinet.43 ( 15 ), 1127 – 1156 ( 2004 ).
   PubMed Web of Science ®Google Scholar
• Chi KN , SpratlinJ , KollmannsbergerCet al. Food effects on abiraterone pharmacokinetics in healthy subjects and patients with metastatic castration-resistant prostate cancer . J. Clin. Pharmacol.55 ( 12 ), 1406 – 1414 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Stuyckens K , SaadF , XuXSet al. Population pharmacokinetic analysis of abiraterone in chemotherapy-naive and docetaxel-treated patients with metastatic castration-resistant prostate cancer . Clin. Pharmacokinet.53 ( 12 ), 1149 – 1160 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Inoue K , ShishidoA , VaccaroNet al. Pharmacokinetics of abiraterone in healthy Japanese men: dose-proportionality and effect of food timing . Cancer Chemother. Pharmacol.75 ( 1 ), 49 – 58 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration Center for Drug Evaluation and Research . Clinical pharmacology and biopharmaceutics review(s): Zytiga . US Food and Drug Administration . www.accessdata.fda.gov/drugsatfda_docs/nda/2011/202379Orig1s000ClinPharmR.pdf .
   Google Scholar
• Stappaerts J , GeboersS , SnoeysJet al. Rapid conversion of the ester prodrug abiraterone acetate results in intestinal supersaturation and enhanced absorption of abiraterone: in vitro, rat in situ and human in vivo studies . Eur. J Pharm. Biopharm.90 , 1 – 7 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Geboers S , StappaertsJ , MolsRet al. The effect of food on the intraluminal behavior of abiraterone acetate in man . J. Pharm. Sci.105 ( 9 ), 2974 – 2981 ( 2016 ).
   PubMed Web of Science ®Google Scholar
• Li R , EvaulK , SharmaKKet al. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer . Clin. Cancer Res.18 ( 13 ), 3571 – 3579 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Dy GK , AdjeiAA . Understanding, recognizing, and managing toxicities of targeted anticancer therapies . CA Cancer J. Clin.63 ( 4 ), 249 – 279 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Liu S , KurzrockR . Understanding toxicities of targeted agents: implications for anti-tumor activity and management . Semin. Oncol.42 ( 6 ), 863 – 875 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Emamekhoo H , LiZ , SharifiN . Clinical significance of D4A in prostate cancer therapy with abiraterone . Cell Cycle14 ( 20 ), 3213 – 3214 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Li Z , BishopAC , AlyamaniMet al. Conversion of abiraterone to D4A drives anti-tumour activity in prostate cancer . Nature523 ( 7560 ), 347 – 351 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Stover JT , MooreRA , DavisK , HarrisonMR , ArmstrongAJ . Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer . Prostate Cancer Prostatic. Dis.18 ( 2 ), 161 – 166 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Espinosa M , FalconA , GutierrezAet al. Pharmacokinetic food-effect study of abiraterone acetate (AA) in patients with metastatic castration resistant prostate cancer (mCRPC): the ABIFOOD trial . J. Clin. Oncol.34 ( Suppl. 2S ), Abstract 227 ( 2016 ).
   Google Scholar
• Leibowitz-Amit R , AtenafuEG , SeahJet al. Low-dose abiraterone (abi) with food in men with metastatic castration-resistant prostate cancer (mCRPC): the Princess Margaret Cancer Centre experience . J. Clin. Oncol.32 ( Suppl. 5S ), Abstract 5077 ( 2014 ).
   Google Scholar
• Szmulewitz RZ , IbraheemAF , PeerCJet al. A prospective international randomized Phase II study evaluating the food effect on the pharmacokinetics (PK) and pharmacodynamics (PD) of abiraterone acetate (AA) in men with castrate resistant prostate cancer (CRPC) . Presented at : American Society of Clinical Oncology Genitourinary Cancers Symposium . Orlando, FL , 16–18 February 2017 ( Poster A176 ).
   Google Scholar
• Xu XS , RyanCJ , StuyckensKet al. Modeling the relationship between exposure to abiraterone and prostate-specific antigen dynamics in patients with metastatic castration-resistant prostate cancer . Clin. Pharmacokinet.56 ( 1 ), 55 – 63 ( 2017 ).
   PubMed Web of Science ®Google Scholar
• Todd M , MeyersML , CharnasR , AcharyaM , MolinaA . Fast and flawed or scientifically sound: the argument for administering oral oncology drugs during fasting . J. Clin. Oncol.30 ( 8 ), 888 – 889 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lin HM , SuriA , WebbIJ , AggarwalS . Relationships between food effects, patient adherence to treatment, and pharmcokinetics of oral anticancer drugs . J. Clin. Oncol.32 ( Suppl. ), Abstract e17614 ( 2014 ).
   Google Scholar